Kevin Brosseau, Canada's fentanyl czar, travelled to Washington on June 15 to present new data on declining opioid-related deaths to U.S. Attorney General Pamela Bondi. The meeting also included Minister of Justice Sean Fraser and Minister of Public Safety Gary Anandasangaree, putting Canadian officials across the table from the senior U.S. law-enforcement official most directly responsible for federal narcotics policy.

The headline figure Brosseau carried south was 6,161 opioid-related deaths in Canada between July 2024 and June 2025—an average of 17 per day. The number is still severe in absolute terms, but it sits within an encouraging trend: Canada recorded a measurable decline in opioid-related deaths in 2024 compared to 2023, the first such drop in recent years. Most apparent opioid deaths remain accidental rather than intentional, a distinction that shapes how prevention resources are allocated.

The Role and Its Origins

Brosseau, a former RCMP officer, was appointed to the role in early 2025 in circumstances shaped as much by U.S. trade negotiations as by domestic public-health needs. The position emerged from talks between Prime Minister Justin Trudeau and President Donald Trump in which tariffs and border enforcement became linked negotiating items. Trump had framed planned tariffs on Canada, Mexico and China partly as leverage to reduce illicit fentanyl flows into the United States; Ottawa's appointment of a named, accountable point person signalled that Canada was taking the file seriously on American terms.

The "czar" title is borrowed directly from U.S. political vocabulary—drug czar, border czar—and its adoption reflects how Canada's positioning on this file has been calibrated for an American audience. Brosseau's mandate is nominally domestic, focused on co-ordinating federal efforts to reduce opioid harm, but his most visible activity since appointment has involved cross-border diplomacy rather than, for example, convening provincial health ministers.

What the Numbers Mean for the Bilateral File

The data Brosseau presented to Bondi serves a specific diplomatic purpose. The Trump administration's case for tariff pressure rested partly on the claim that Canada was not doing enough to stop fentanyl precursors and finished product at the border. Canadian officials have consistently disputed the scale of that flow—the volume of fentanyl entering the U.S. from Canada is a fraction of what crosses from Mexico—but data showing a domestic death decline gives Brosseau something concrete to present: evidence of operational progress, not just a jurisdictional argument.

Whether that evidence shifts Bondi's or the administration's approach is uncertain. The U.S. political incentive structure on fentanyl is not primarily about Canadian import volumes; it reflects domestic accountability concerns. Ottawa's interest is in preventing this file from further complicating the bilateral relationship over a problem that, statistically, Canada did not create and cannot fully control.

The June 15 meeting is the most recent in a sequence of high-level engagements on this file since Brosseau's appointment in February 2025. That the czar is still making the Washington circuit more than a year into the role, now with updated mortality data in hand, indicates the file remains actively managed at the political level on both sides of the border. It has not been quietly shelved, but neither has it been settled.